TITLE

Thai Trial Analysis Shows Antibody Competition

AUTHOR(S)
Breindl, Anette
PUB. DATE
May 2013
SOURCE
BioWorld Today;5/13/2013, Vol. 24 Issue 91, Special section p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article presents an overview of the RV144 trial of ALVAC HIV of Sanofi SA and AIDSVAX B/E HIV vaccine of VaxGen Inc. by a team from Duke University which was published in the May 6, 2013 online edition of the "Proceedings of the National Academy of Sciences.
ACCESSION #
87593109

 

Related Articles

  • Clinical development of fedratinib discontinued.  // Reactions Weekly;Nov2013, Issue 1477, p2 

    The article discusses the pharmaceutical company Sanofi's decision to discontinue clinical trials and development of the drug fedratinib following cases of Wernicke's encephalopathy.

  • 'JAK'ing Up Myelofibrosis; Sanofi's Phase III Data Solid. Boggs, Jennifer // BioWorld Today;5/20/2013, Vol. 24 Issue 96, p1 

    The article discusses positive results from Paris, France-based pharmaceutical company Sanofi SA's Phase III trial of the Janus kinase inhibitor, SAR302503, for myelofibrosis. The trial also involved the evaluation of associated symptoms as measured by total symptom score using symptoms...

  • In the multiple sclerosis race, others 'Campath' Genzyme: FDA delivers CRL. Osborne, Randy // BioWorld Today;12/31/2013, Vol. 24 Issue 250, p1 

    The article discusses the complete response letter (CRL) of the U.S. Food and Drug Administration (FDA) on the Lemtrada CD52-targeting antibody from Genzyme Corp. biotechnology company. It emphasizes the claim of the FDA that the approval of the drug requires more trials. It mentions that the...

  • Sanofi and its Subsidiary Genzyme to Feature More than 20 Data Presentations at the ECTRIMS/ACTRIMS Congress.  // Biomedical Market Newsletter;10/24/2011, Vol. 21, p677 

    The article reports on the plan of Sanofi SA and its subsidiary Genzyme Corp. to feature more than 20 data presentations on multiple sclerosis (MS) at the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS/ACTRIMS) in...

  • Trial Results.  // CenterWatch Weekly;4/14/2014, Vol. 18 Issue 15, p9 

    The article presents the results of several clinical trials as of 2014. In cardiology, pharmaceutical companies Sanofi SA and Regeneron Pharmaceuticals Inc. released the results of a phase II study of alirocumab for the treatment of low-density lipoprotein-cholesterol (LDL-C). In oncology, Synta...

  • Ten Drugmakers Team Up to Improve Testing Process.  // MondayMorning;9/24/2012, Vol. 20 Issue 36, p1 

    The article reports on the collaboration among 10 European and U.S. drugmakers to improve the way of testing drugs. In September 2012, the drugmakers revealed the nonprofit organization they have started called TransCelerate BioPharma to deal with the problem on drug testing. Participants...

  • Trials `a must' for disputed cholesterol drugs. Vines, G. // New Scientist;2/22/92, Vol. 133 Issue 1809, p11 

    Reports on the dispute in Great Britain over cholesterol-lowering drugs. The need for large trials of a new generation of these drugs, known as statins; The two sides of the dispute; Press reports that have led to fears of a consumer backlash against the drugs.

  • The limited precision of phase I trials. Christian, Michaele C.; Korn, Edward L. // JNCI: Journal of the National Cancer Institute;11/16/94, Vol. 86 Issue 22, p1662 

    Editorial. Criticizes conventional phase I trial designs' tendency to give inappropriate dose recommendations. National Cancer Institute (NCI) Cancer Therapy Evaluation Program's commitment to exploring alternative phase I trial designs; Strategies for improving precision of estimating the...

  • Toxicity tests minus animals? Gillis, Anna Maria // BioScience;Mar1993, Vol. 43 Issue 3, p137 

    Reports that cellular and tissue techniques are in, but as long as public safety is at stake, animals will continue to be used in testing. The work of toxicology; In vitro models; Human skin modeling; What tests can determine; Characteristics of a proper model; Validation.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics